Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma
Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Mat...
Gespeichert in:
Veröffentlicht in: | Journal of clinical apheresis 2021-08, Vol.36 (4), p.628-633 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 633 |
---|---|
container_issue | 4 |
container_start_page | 628 |
container_title | Journal of clinical apheresis |
container_volume | 36 |
creator | Yang, John Jeongseok Ryu, Kyong‐Suk Kim, Jin Seok Chung, Yousun Kim, Hyungsuk Hwang, Sang‐Hyun Oh, Heung‐Bum Ko, Dae‐Hyun |
description | Background
Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols.
Aims
This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation.
Materials & Methods
Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described.
Results
The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported.
Discussion
While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events.
Conclusions
Use of incompatible group A or B plasma is a viable option when group AB plasma is limited. |
doi_str_mv | 10.1002/jca.21904 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2522400275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2522400275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</originalsourceid><addsrcrecordid>eNp1kT1PwzAQhi0EoqUw8AdQJBYY0vrrkngsVflSJRaYIzdx2lRJHOwY6L_HJS0DEpPtu8ePTvcidEnwmGBMJ5tMjikRmB-hIcEiCQnB5BgNccxYSDmIATqzdoMxFoLBKRowJgAD8CFq5h-ycrIrdRPoIrCyUN12d3O2bFZB2WS6bn17WamgraStZVBoE3RrZWSrXFdmh7L6ytayWakgd2b31a616aR_e9n0bk-do5NCVlZd7M8Rerufv84ew8XLw9NsuggzBoyHxRKSiEZJLAsuMwKJEARHLCeJlDhnisY0VzkoiBLCCAeIOU1y32RJxDClbIRuem9r9LtTtkvr0maqqmSjtLMpBUq5X10MHr3-g260M42fzlMgeEwAIk_d9lRmtLVGFWlrylqabUpwugsh9SGkPyF49mpvdMta5b_kYesemPTAZ1mp7f-m9Hk27ZXf2SuPZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2559471556</pqid></control><display><type>article</type><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</creator><creatorcontrib>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</creatorcontrib><description>Background
Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols.
Aims
This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation.
Materials & Methods
Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described.
Results
The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported.
Discussion
While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events.
Conclusions
Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</description><identifier>ISSN: 0733-2459</identifier><identifier>EISSN: 1098-1101</identifier><identifier>DOI: 10.1002/jca.21904</identifier><identifier>PMID: 33950554</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>ABO Blood-Group System ; Agglutinins - chemistry ; Apheresis ; Blood Banks - supply & distribution ; Blood Group Incompatibility - therapy ; desensitization ; Graft Survival ; Hemolysis ; Humans ; incompatible ; Kidney Transplantation - adverse effects ; Patient Safety ; Plasma ; Plasma - immunology ; Plasma Exchange - methods ; Plasmapheresis ; safety ; therapeutic plasma exchange ; Transfusion Reaction ; Transplantation - methods ; Treatment Outcome</subject><ispartof>Journal of clinical apheresis, 2021-08, Vol.36 (4), p.628-633</ispartof><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</citedby><cites>FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</cites><orcidid>0000-0002-7739-1009 ; 0000-0002-9781-0928</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjca.21904$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjca.21904$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33950554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, John Jeongseok</creatorcontrib><creatorcontrib>Ryu, Kyong‐Suk</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Chung, Yousun</creatorcontrib><creatorcontrib>Kim, Hyungsuk</creatorcontrib><creatorcontrib>Hwang, Sang‐Hyun</creatorcontrib><creatorcontrib>Oh, Heung‐Bum</creatorcontrib><creatorcontrib>Ko, Dae‐Hyun</creatorcontrib><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><title>Journal of clinical apheresis</title><addtitle>J Clin Apher</addtitle><description>Background
Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols.
Aims
This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation.
Materials & Methods
Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described.
Results
The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported.
Discussion
While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events.
Conclusions
Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</description><subject>ABO Blood-Group System</subject><subject>Agglutinins - chemistry</subject><subject>Apheresis</subject><subject>Blood Banks - supply & distribution</subject><subject>Blood Group Incompatibility - therapy</subject><subject>desensitization</subject><subject>Graft Survival</subject><subject>Hemolysis</subject><subject>Humans</subject><subject>incompatible</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Patient Safety</subject><subject>Plasma</subject><subject>Plasma - immunology</subject><subject>Plasma Exchange - methods</subject><subject>Plasmapheresis</subject><subject>safety</subject><subject>therapeutic plasma exchange</subject><subject>Transfusion Reaction</subject><subject>Transplantation - methods</subject><subject>Treatment Outcome</subject><issn>0733-2459</issn><issn>1098-1101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kT1PwzAQhi0EoqUw8AdQJBYY0vrrkngsVflSJRaYIzdx2lRJHOwY6L_HJS0DEpPtu8ePTvcidEnwmGBMJ5tMjikRmB-hIcEiCQnB5BgNccxYSDmIATqzdoMxFoLBKRowJgAD8CFq5h-ycrIrdRPoIrCyUN12d3O2bFZB2WS6bn17WamgraStZVBoE3RrZWSrXFdmh7L6ytayWakgd2b31a616aR_e9n0bk-do5NCVlZd7M8Rerufv84ew8XLw9NsuggzBoyHxRKSiEZJLAsuMwKJEARHLCeJlDhnisY0VzkoiBLCCAeIOU1y32RJxDClbIRuem9r9LtTtkvr0maqqmSjtLMpBUq5X10MHr3-g260M42fzlMgeEwAIk_d9lRmtLVGFWlrylqabUpwugsh9SGkPyF49mpvdMta5b_kYesemPTAZ1mp7f-m9Hk27ZXf2SuPZg</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Yang, John Jeongseok</creator><creator>Ryu, Kyong‐Suk</creator><creator>Kim, Jin Seok</creator><creator>Chung, Yousun</creator><creator>Kim, Hyungsuk</creator><creator>Hwang, Sang‐Hyun</creator><creator>Oh, Heung‐Bum</creator><creator>Ko, Dae‐Hyun</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7739-1009</orcidid><orcidid>https://orcid.org/0000-0002-9781-0928</orcidid></search><sort><creationdate>202108</creationdate><title>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</title><author>Yang, John Jeongseok ; Ryu, Kyong‐Suk ; Kim, Jin Seok ; Chung, Yousun ; Kim, Hyungsuk ; Hwang, Sang‐Hyun ; Oh, Heung‐Bum ; Ko, Dae‐Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-fb5862687af4ac158991063d18aa0d3e272ded5e5681314557428d8aa38630223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ABO Blood-Group System</topic><topic>Agglutinins - chemistry</topic><topic>Apheresis</topic><topic>Blood Banks - supply & distribution</topic><topic>Blood Group Incompatibility - therapy</topic><topic>desensitization</topic><topic>Graft Survival</topic><topic>Hemolysis</topic><topic>Humans</topic><topic>incompatible</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Patient Safety</topic><topic>Plasma</topic><topic>Plasma - immunology</topic><topic>Plasma Exchange - methods</topic><topic>Plasmapheresis</topic><topic>safety</topic><topic>therapeutic plasma exchange</topic><topic>Transfusion Reaction</topic><topic>Transplantation - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, John Jeongseok</creatorcontrib><creatorcontrib>Ryu, Kyong‐Suk</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Chung, Yousun</creatorcontrib><creatorcontrib>Kim, Hyungsuk</creatorcontrib><creatorcontrib>Hwang, Sang‐Hyun</creatorcontrib><creatorcontrib>Oh, Heung‐Bum</creatorcontrib><creatorcontrib>Ko, Dae‐Hyun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, John Jeongseok</au><au>Ryu, Kyong‐Suk</au><au>Kim, Jin Seok</au><au>Chung, Yousun</au><au>Kim, Hyungsuk</au><au>Hwang, Sang‐Hyun</au><au>Oh, Heung‐Bum</au><au>Ko, Dae‐Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma</atitle><jtitle>Journal of clinical apheresis</jtitle><addtitle>J Clin Apher</addtitle><date>2021-08</date><risdate>2021</risdate><volume>36</volume><issue>4</issue><spage>628</spage><epage>633</epage><pages>628-633</pages><issn>0733-2459</issn><eissn>1098-1101</eissn><abstract>Background
Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols.
Aims
This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation.
Materials & Methods
Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described.
Results
The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported.
Discussion
While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events.
Conclusions
Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>33950554</pmid><doi>10.1002/jca.21904</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7739-1009</orcidid><orcidid>https://orcid.org/0000-0002-9781-0928</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0733-2459 |
ispartof | Journal of clinical apheresis, 2021-08, Vol.36 (4), p.628-633 |
issn | 0733-2459 1098-1101 |
language | eng |
recordid | cdi_proquest_miscellaneous_2522400275 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
subjects | ABO Blood-Group System Agglutinins - chemistry Apheresis Blood Banks - supply & distribution Blood Group Incompatibility - therapy desensitization Graft Survival Hemolysis Humans incompatible Kidney Transplantation - adverse effects Patient Safety Plasma Plasma - immunology Plasma Exchange - methods Plasmapheresis safety therapeutic plasma exchange Transfusion Reaction Transplantation - methods Treatment Outcome |
title | Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A03%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20safety%20of%20using%20incompatible%20plasma%20for%20therapeutic%20plasma%20exchange%20during%20shortage%20of%20AB%20plasma&rft.jtitle=Journal%20of%20clinical%20apheresis&rft.au=Yang,%20John%20Jeongseok&rft.date=2021-08&rft.volume=36&rft.issue=4&rft.spage=628&rft.epage=633&rft.pages=628-633&rft.issn=0733-2459&rft.eissn=1098-1101&rft_id=info:doi/10.1002/jca.21904&rft_dat=%3Cproquest_cross%3E2522400275%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2559471556&rft_id=info:pmid/33950554&rfr_iscdi=true |